Persistent infection of hepatitis C virus (HCV) is one of the leading causes of end-stage liver disease (ESLD), such as decompensated cirrhosis and liver cancer. Of particular note, nearly half of HCV-infected people in the United States are reported to be heavy drinkers. This particular group of patients is known to rapidly progress to the ESLD. Although accelerated disease progression among alcohol abusers infected with HCV is clinically well recognized, the molecular pathophysiology behind this manifestation has not been well elucidated. Hepatocytes metabolize ethanol (EtOH) primarily through two steps of oxidative catabolism in which alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) play central roles. The ADH-ALDH pathway also governs the metabolism of retinol (vitamin A) to its transcriptionally active metabolite, retinoic acid (RA). In this study, we defined that the ADH-ALDH pathway serves as a potent antiviral host factor in hepatocytes, which regulates the expression of interferon (IFN)-stimulated genes (ISGs) by biogenesis of RA. ISGs constitute over 300 antiviral effectors, which cooperatively govern intracellular antiviral innate immunity. Our study revealed that intracellular RA levels greatly influence ISG expression under basal conditions. Moreover, RA augments ISG induction in response to viral infection or exposure to IFN in a gene-specific manner. Lastly, our results demonstrated that EtOH attenuates the antiviral function of the ADH-ALDH pathway, which suggests the possibility that EtOH-retinol metabolic competition is one of the molecular mechanisms for the synergism between HCV and alcohol abuse in liver disease progression. Conclusions: RA plays a critical role in the regulation of intracellular antiviral innate immunity in hepatocytes. (HEPATOLOGY 2016;63:1783-1795 
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O ver 200 million people worldwide are chronically infected with hepatitis C virus (HCV). (1) In the United States, at least 3.5 million people suffer from chronic HCV infection with recent significant increase observed among intravenous (IV) drug users. (2, 3) Of particular note, half of the HCV-infected population in the United States has been reported to be heavy drinkers. (4) This group of patients exhibits pronounced HCV replication and refractoriness to antiviral therapy, which results in a 30-and 48-fold increase in developing decompensated cirrhosis and hepatocellular carcinoma, respectively. (5) This synergism between chronic HCV infection and alcohol abuse is well recognized; however, the underlying molecular pathophysiology has not been well understood.
Hepatocytes play a central role in ethanol (EtOH) metabolism through alcohol dehydrogenase (ADH) and, to a lesser extent, through cytochrome P450-2E1 (CYP2E1) oxidation to acetaldehyde. (6) Acetaldehyde is subsequently metabolized to acetate by aldehyde dehydrogenase (ALDH). (6) The relevance of metabolic by-product(s) of EtOH and/or cellular response in the pathogenesis of HCV has not been well understood, primarily because of the lack of appropriate research tools. Here, we established Huh7 cell-line based systems that express individual enzymes required in EtOH metabolism. Of great interest, our results demonstrate that the ADH-ALDH pathway serves as a potent antiviral element; whereas, CYP2E1 is a proviral host factor. We also found that the antiviral phenotype of the ADH-ALDH pathway is significantly attenuated in the presence of EtOH.
ADH also plays a critical role in the conversion of retinol (ROL) to retinaldehyde (RAL), followed by the oxidation of RAL to retinoic acid (RA) by ALDH. (7) For ADH1, which is abundantly expressed in hepatocytes, ROL is the far preferred substrate as compared to EtOH. However, the ROL concentration in serum is much lower than the ADH1 Km for ROL. In contrast, the blood EtOH concentration of heavy drinkers often approaches or surpasses the ADH1 Km for EtOH, thus providing a situation in which biogenesis of RA is impaired. (7, 8) This led us to hypothesize that EtOH-ROL metabolic competition might be an underlying mechanism for the synergism between HCV and alcoholism.
Numerous studies indicate that RA exhibits antiviral activities against a variety of pathogens. (9) (10) (11) The antiviral properties of RA have been mainly explained in the context of professional innate immune cells and adaptive immunity (12) ; however, the role in innate immunity in terminally differentiated nonimmune cells such as hepatocytes remains undefined. Interferon (IFN)-stimulated genes (ISGs), constituting over 300 genes, represent the antiviral innate immune effectors that cooperatively restrict the viral life cycle. (13) ISG expression at basal levels determines cellular susceptibility to viral infection. (14) During infection, host cells robustly induce additional ISGs upon pattern recognition receptor sensing of pathogen-associated molecular patterns (PAMPs), such as viral genome. (15) This event also results in the secretion of endogenous type 1 IFN, such as IFN-b. IFN then promotes expression of the grossly redundant ISGs in both infected and neighboring cells by activation of Janus kinase/signal transducer and activator of transcription (Jak-STAT) signaling. The magnitude of the additional ISG induction is a major predictor of clinical outcome. (16) Although a few ISGs have been reported as RA inducible, (15, 17, 18) the fundamental role of RA in regulation of ISGs has not been determined. Our findings revealed that restoration of the ADH-ALDH pathway in Huh7 cells greatly enhanced ISG expression under both basal and induced conditions in a gene-specific manner, which was associated with successful clearance of the pathogen. Moreover, our study revealed that the EtOH-inducible enzyme, CYP2E1, (19) significantly attenuates RAmediated gene expression and thus supports viral replication.
In summary, our study demonstrated that impaired biogenesis of RA leads to decreased expression of ISGs in hepatocytes, thereby providing a molecular explanation for the synergism between HCV infection and alcoholic liver disease (ALD).
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Materials and Methods
CELLS AND TRANSFECTION
Huh7 cells were maintained as previously described (20) and transfected with TransIT-LT1 (Mirus Bio LLC, Madison, WI) or TransIT-messenger RNA (Mirus Bio LLC). Huh7 stable cell lines expressing hADH1B or hCYP2E1 were established by lentiviral transduction (System Biosciences, Inc., Mountain View, CA). Lentiviral transduction was carried out at multiplicity of infection (MOI) 5 followed by Puromycin selection (2 lg/mL) to established polyclonal (pooled) cell lines. Primary human hepatocytes (PHHs) were obtained from Life Technologies (Carlsbad, CA). Primary mouse hepatocytes of C57BL/6 were obtained from Non-Parenchymal Liver Cell Core at Southern California Research Center for ALPD and Cirrhosis.
VIRUSES
Lentiviral and HCV (JFH1) particle was propagated and tittered as described previously (20) . (20) Huh7 subgenomic replicon cells were established through G418 (400 ug/mL) selection upon in vitro transcribed subgenome transfection. The HCV pseudoparticle system was propagated as previously described. (21) Sendai virus (SeV) was obtained from Charles River Laboratories (Wilmington, MA), and the infection (10-100 HAU/ mL) was conducted in serum-free Dulbecco's modified Eagle's medium (DMEM) for 1 hour at 378C.
CHEMICAL MEASUREMENT OF EtOH AND ACETAMINOPHEN PROTEIN ADDUCTS
EtOH treatments were carried out at 10, 12.5, and/ or 50 mM, which correspond to the physiological blood-alcohol concentration among alcoholics of 0.046%, 0.057%, and 0.229%, respectively. (22) EtOH in the cell-culture medium was measured by gas chromatography (GC) similarly to a previous report. (23) Concentrations of acetaminophen (APAP) protein adducts were measured by high-performance liquid chromatography with electrochemical detection (HPLC-EC), as described previously. (24) Acetaldehyde, acetate, all trans retinoic acid (ATRA), and all trans ROL were obtained from Sigma-Aldrich (St. Louis, MO). EC23 (ATRA analog) was purchased from Tocris. RAR antagonist (4310) was described previously. (25) STATISTICAL ANALYSIS P values were obtained using the Student t test, and results were considered significant at P < 0.05.
Result
RESTORATION OF THE EtOH METABOLIC PATHWAYS IN HUH7 CELLS
The ADH and ALDH families are comprised of 8 and 10 family members, respectively. (6) We first conducted meta-analysis of National Center for Biotechnology Information/Gene Expression Omnibus microarray data to determine the isoforms of ADHs and ALDHs that are predominantly expressed in human hepatocytes. Consistent with previous reports, this analysis demonstrated that hepatocytes express the following isoforms; (1) ADH: ADH1 (A, B, and C), 4, 6, and FE1; and (2) ALDH: ALDH1A1, ALDH2, and ALDH4A1 (Supporting Fig. 1A,B) . (26) Because in vitro HCV studies are restricted to use of Huh7 cells, we assessed expression of liver-dominant ADHs and ALDHs in Huh7 cells. The gene and protein expression analysis demonstrated that Huh7 cells lack expression of these ADHs and CYP2E1 (Fig.  1A,B) . However, they preserved expression of ALDHs, suggesting that reconstitution of ADHs should restore their EtOH metabolism capability.
Among the enzymes responsible for conversion of EtOH to acetaldehyde in hepatocytes, ADH1 is the most abundant in hepatocytes. (7, 26) Thus, ADH1 is known to be the primary ADH involved in liver EtOH metabolism. Next, we tested the enzymatic activity of ADH1B (a delegate of ADH1) on EtOH by determining the reduction rate of nicotinamide adenine dinucleotide (NAD1) conversion to NADH. NAD1 is a coenzyme required for oxidation of EtOH, serving as an electron acceptor; and therefore the conversion rate can be used to indirectly monitor ADH activity. (26) Huh7 cellular lysates upon ADH1B overexpression exhibited potent activity whereas ADH4-and ADH6-expressing cells showed negligible activity (Fig. 1C) . Next, we evaluated whether reconstitution of ADH1B or CYP2E1 restores EtOH metabolic function in Huh7 cells. The result showed that overexpression of ADH1B, and CYP2E1, to a lesser extent, restored metabolism to physiological concentrations of EtOH (22) (Fig. 1D ).
In addition to CYP1A2, 3A4, and 2D6, CYP2E1 is also known to catabolize xenobiotics such as APAP. Upon metabolism of APAP, CYPs produce the electrophile, N-acetyl-p-benzoquinone imine (NAPQI), which exhibit toxicity through covalent binding to cellular proteins and nucleic acids. (27) Thus, we tested whether CYP2E1 in Huh7 cells produces APAP protein adducts using HPLC-EC. Cell lysates from CYP2E1-expressing cells contained higher NAPQI protein adducts compared to control condition (Fig.  1E) . These results assure that Huh7 cells offer an environment for these enzymes to be functional, although these capacities appeared inferior to that of primary hepatocytes likely because of the relative abundance (Supporting Fig. 1C ).
THE ADH-ALDH PATHWAY IS A POTENT ANTIVIRAL HOST FACTOR
Restoration of EtOH metabolic capacity in Huh7 cells enabled us to investigate the association between EtOH metabolic pathways and the HCV life cycle. Surprisingly, transient ADH1B overexpression in Huh7 cells harboring HCV subgenomic replicon (HCV-SGR) dramatically suppressed HCV replication ( Fig. 2A,B) . In contrast, overexpression of CYP2E1 was associated with an enhancement of HCV replication. Moreover, the antiviral effect of ADH1B was reduced in the presence of EtOH (Fig. 2B ). Next, we tested whether ADH1B affects the efficiency in establishing viral life cycle by HCV-SGR replicon transduction assay. Transfection of HCV subgenome in Huh7 cells that stably express ADH1B demonstrated a significantly lesser number of HCVreplicating foci formation; however, the difference between control and ADH1B cells diminished upon EtOH treatment (Fig. 2C) . These results indicate that the ADH-ALDH pathway serves as an antiviral host factor in the absence of EtOH. Furthermore, our results suggest that either (1) the EtOH metabolic byproducts generated by ADH1B may offer a suitable environment for efficient HCV replication or (2) EtOH prohibits the biogenesis of antiviral molecules produced by the ADH-ALDH pathway. To distinguish between these possibilities, we addressed whether EtOH metabolites increase HCV replication efficiency. The results showed that neither acetaldehyde nor acetate treatment changed viral replication efficiency (Supporting Fig. 2A,B) .
To further understand how the ADH-ALDH pathway suppresses HCV, we assessed the effect of ADH1B expression on each stage of the viral life cycle. First, an HCV pseudo particle containing a green fluorescent protein (GFP) reporter was employed to test the effect of ADH1B expression on viral entry. Under these conditions, ADH1B expression in Huh7 cells was found to have a negligible effect on viral entry (Fig.  2D ). Next, we examined the effect of ADH1B expression on genome replication using reverse-transcription polymerase chain reaction (RT-PCR). The abundance of each region of the viral genome decreased with distance from the replication initiation site (5 0 UTR [untranslated region]) of the viral genome, especially in ADH1B-expressing cells (Fig. 2E ). This result may suggest that the ADH-ALDH pathway restricts HCV by promoting premature termination of genome replication. Taken together, these results indicate that the ADH-ALDH pathway restricts HCV at the genome replication/translation stage.
SHARED ANTIVIRAL PROPERTIES OF LIVER-DOMINANT ADH ISOFORMS
We extended our investigations to the other liverdominant ADHs to determine whether these enzymes also suppress HCV. To accomplish this, we expressed ADH4 and ADH6 in Huh7-SGR cells and assessed their antiviral potency. The result showed that expression of ADH4 and ADH6 in HCV-SGR cells exhibited a comparable degree of viral suppression as to that observed with ADH1B expression (Fig. 3A) . Similar results were observed with immunofluorescent microscopic analysis and protein analysis, wherein these ADH isoforms potently inhibited HCV (Fig. 3B,C) , indicating that the antiviral activity of ADH is not unique to ADH1B, but is shared among other ADHs. Analysis of ADH enzymatic activity revealed that the different ADHs possess distinctive EtOH metabolic activity (Fig. 1C) . These ADHs have also been shown to metabolize ROL, (7, 26) leading to the possibility that the ADH-ALDH pathway suppresses HCV through metabolism of ROL. To test this possibility, cell lysates containing these ADH isoforms were treated with ROL in the presence of NAD, and the enzymatic activity was assessed by the rate of NAD1 reduction to NADH. All ADHs tested were found to exhibit comparable activity on ROL (Supporting Fig.  3A ). In addition, the antiviral effect of ADH1B but not ADH4 was antagonized by EtOH (Supporting Fig. 3B) , likely reflecting the enzymatic activity on EtOH (Fig. 1C) as well as KiEtOH to ROL. (7) These observations collectively suggest that the antiviral activity of ADH may be through the metabolism of ROL to the biogenesis of RA and EtOH impairs the antiviral effect of the ADH-ALDH pathway, depending on their affinity to EtOH.
THE ADH-ALDH PATHWAY REGULATES GENE EXPRESSION THROUGH BIOGENESIS OF RA
To test whether ADH1B expression enables the production of RA from ROL in Huh7 cells, a few well-accepted RA-inducible genes' expression were assessed by quantitative RT-PCR. The result showed that ADH1B-expressing cells robustly induced these genes in response to ROL treatment (Fig. 4A) . RA regulates gene expression by binding to the heterodimer nuclear receptor complex that is comprised of retinoic acid receptor/retinoid X receptor (RAR-RXR). (28) The RAR-RXR heterodimer binds preferentially to a retinoic acid response element (RARE), which contains two receptor cognate-binding sequences typically separated by 5 base pairs (bp), direct repeat 5 (DR5). RA binding to the RAR leads to recruitment of coactivators and activation of gene transcription.
(28) Therefore, we investigated whether ADH1B expression in Huh7 cells impacts RARmediated gene expression using a RARE-containing luciferase reporter. First, a series of RARE luciferase reporters comprising of 1, 3, and 5 bp separated RARE (DR1, DR3, or DR5, respectively) were expressed in Huh7 cells and the response to ATRA treatment was monitored. Addition of ATRA selectively induced significant luciferase activity only in the DR5 RARE reporter (Supporting Fig. 4A ). Moreover, the DR5 reporter was found to exhibit increased and reduced activity in response to an RA agonist (EC23) or an RAR antagonist (4310), respectively (Supporting Fig. 4B,C) . Given these results, the RARE-DR5 reporter was employed as a surrogate to follow RAR activity. After cotransfection of the RARE-DR5 into Huh7 cells and treatment with ROL, coexpression of ADH1B induced activation of RARE-DR5 (Fig. 4B ). In addition, both gene expression analysis and reporter assay results showed that ADH1B expression enhances RA-gene regulation even under the basal condition. We speculate that this is likely because of the metabolism of up to 50 nM of ROL in standard 10% fetal bovine serum DMEM by the ADH1B-ALDH pathway. To further test the influence of the ADH1B-ALDH pathway in gene regulation, a quantitative RT-PCR array comprising RA-regulated genes was employed (Fig. 4C,D) . The result demonstrated that ADH1B expression globally up-regulates RA-inducible genes at the basal condition, and the degree of the up-regulation was significantly higher than that of exogenous ROL-treated control Huh7 cells. Next, we compared the gene expression changes observed in Huh7 cells that express ADH1B to that of PHH treated with ATRA. These results showed identical patterns (Fig. 4C,D) , thereby indicating that reconstitution of ADH1B in Huh7 cells leads to production of RA from ROL. This notion is also well supported by the fact that the control cells minimally changed the expression of RAregulated genes even in response to exogenous ROL (Fig. 4A-C) . 
CRITICAL ROLE OF THE ADH-ALDH PATHWAY FOR THE ISG EXPRESSION
Next, we directly tested whether RA alone was sufficient to suppress HCV. For this purpose, HCV-SGR cells were treated with RA and this led to dramatic inhibition of viral replication (Fig. 5A) . RA is known to play an important role in a variety of cellular functions, including cell proliferation, death, and differentiation. (8) To better understand the mechanisms underlying RA suppression of HCV replication, we initially tested whether the ADH-ALDH pathway influences cell growth and/or susceptibility to cell death, which may nonspecifically influence viral replication given that the life cycle heavily relies on the cellular machinery. Expression of ADH1B neither changed cell growth/proliferation nor cell viability (Supporting Fig. 5A,B) . These results led us to hypothesize that the ADH-ALDH pathway plays a role in the regulation of antiviral host factors such as ISGs for suppression of HCV.
Clinical studies reported that RA enhances the response to IFN-based antiviral therapy. (11, 29) These observations suggest that expression of ISGs could be governed, at least partially, by RA. To further explore this hypothesis, we conducted a bioinformatics search of ISG (446 genes) promoter and found that 88% of the regulatory region of ISGs contain RARE-DR5 sequence (Supporting Table 1 ). This observation suggests that up-regulation of ISGs by RA may underlie the ADH-ALDH-mediated suppression of HCV.
To further test this idea, we first investigated whether RA augments the expression of ISGs in terminally differentiated PHHs. These experiments showed that ATRA treatment increased the basal expression level of, at least, a few selected ISGs (Fig.  5B) . In addition, the RA treatment significantly enhanced ISG expression in response to type 1 IFN, well supporting aforementioned clinical observations (Fig. 5B) . Similarly, the synthetic ATRA analog (EC23) enhanced the IFN-mediated ISG induction in PHHs (Supporting Fig. 5C ). These observations with noncancerous primary cells further indicate the critical roles of RA in ISG expression in hepatocytes.
Next, we tested whether the ADH-ALDH pathway enhances expression of ISGs in Huh7 cells. Gene expression analyses showed that ADH1B expression increases ISG expression under basal conditions (Fig.  5C,E) . We also tested whether ADH1B expression augments ISG expression in the induced condition with HCV-PAMP-RNA or IFNb treatment. These are the ligands of two distinct ISG induction pathways: retinoic acid-inducible gene I (RIG-I) or the Jak-STAT pathway, (15) which leads to robust induction of ISGs during infection in infected or neighboring cells, respectively. The result showed that ADH1B expression substantially increased ISG expression in response to these ligands at both the message (Fig. 5C,E ) and protein level (Fig. 5D,F) . Last, we also found that ADH1B expression has negligible effect on the signaling activation potency by these ligands (Supporting Fig. 5D,E) , suggesting that the augmentation of ISG expression by RA is likely at the promoter level.
SELECTIVE UP-REGULATION OF ISGs BY THE ADH-ALDH PATHWAY
Given chromatin remodeling activity of RAR-RXR, we hypothesized that RA regulates ISG expression at the promoter level.
(28) Thus, we speculated that the effect of the ADH-ALDH pathway on ISG induction is highly dependent on the accessibility of activated RAR-RXRs to individual gene promoters, rather than indiscriminate global gene up-regulation. Thus, we assessed the pattern of ISG expression in ADH1B-expressing cells using a quantitative RT-PCR array. In agreement with our hypothesis, ADH1B-expressing cells enhanced ISG expression in a gene-specific manner under both basal conditions and during acute HCV (JFH-1) infection (Fig. 6A) . Of note, the upregulated ISGs include well-studied anti-HCV genes, such as IFIT1 and IFITM1. Furthermore, HCV replication efficiency in ADH1B-expressing cells demonstrated an inverse association with the degree of ISG inducibility (Fig. 6B,C) . Last, we challenged Huh7 cells expressing ADH1B with SeV, which induces ISGs in a RIG-I signaling-dependent manner similar to HCV. (15) ADH1B expression was found to attenuate viral replication efficiency, which is correlated with degree of ISG induction (Supporting Fig. 6A,B) . These observations indicate that the ADH-ALDH pathway restricts viral infection through augmentation of ISG expression at the gene promoter/enhancer level. 
TWO DISTINCT EtOH METABOLIZING PATHWAYS IMPAIR RA REGULATION OF INTRACELLULAR INNATE IMMUNITY
Our results suggest that the impairment of RAmediated ISG regulation in hepatocytes serves as, at least in part, an underlying mechanism for pronounced HCV replication among alcoholics. To further test this idea, we assessed whether EtOH attenuates RARmediated gene regulation. Indeed, the analysis with the RARE-DR5 reporter system (Supporting Fig. 7A ) and quantitative RT-PCR analysis (Fig. 7A ) demonstrated that EtOH impaired RA gene regulation in a dosedependent manner. Accordingly, the cell lysates from ADH1B-expressing cells demonstrated comparable enzymatic activity on both EtOH and ROL, especially at higher concentrations (Fig. 7B) . Moreover, the effect of ADH1B in enhancing ISG expression was attenuated in the presence of EtOH (Supporting Fig. 7B ). These observations suggest that EtOH-ROL competition attenuates RA-mediated ISG expression.
Recent evidence has shown that CYP2E1 potently catabolize RA to transcription inactive polar metabolites. (30) CYP2E1 is an EtOH-inducible enzyme that plays a role in EtOH metabolism (19) (Supporting Fig.  7C and Fig. 1D ). Of note, our results (Fig. 2B) demonstrated that HCV replication was enhanced upon CYP2E1 expression. Thus, we hypothesized that CYP2E1 expression in hepatocytes can be a secondary mechanism that impairs RA regulation of ISG expression. An assay utilizing the RARE-DR5 reporter showed that RA-mediated gene regulation was significantly attenuated in the presence of CYP2E1 both under basal and induced conditions (Fig. 7C and Supporting 7D ). Interestingly, our observation suggests that CYP2E1 catabolic activity on ATRA is nearly comparable to that of CYP26A1, which is the most critical RAcatabolizing enzyme with the Km/RA 10 nM. (31) This suggests that CYP2E1 may preferentially catabolize RA, as compared to other substrates such as EtOH or APAP, and may play a role in the impairment of ISG expression. Consistent with our findings with the HCV-SGR system (Fig. 2B) , expression of CYP2E1 substantially increased susceptibility to HCV infection (Fig. 7D) .
Last, we tested the effect of EtOH in ISG expression with human primary hepatocytes, in which both EtOH-ROL competition on the ADH-ALDH pathway and CYP2E1 induction contribute to depletion of RA. The results showed EtOH treatment dramatically impaired expression of ISGs (Fig. 7E ).
Discussion
Alcohol is the most common intoxicating substance in the United States. Alcoholics are known to have a significantly higher risk of acquiring HCV, owing to the high prevalence of IV drug use in this population. (32) The combination of HCV infection and alcohol abuse rapidly progress to end-stage liver diseases (5, 33) ; however, the molecular mechanism underlying this phenomenon has been unclear.
Our study demonstrated that the ADH-ALDH pathway is a potent antiviral pathway. We also found that the antiviral effect of ADH-ALDH pathway is mediated by the metabolism of ROL to the biogenesis of RA. Moreover, the antiviral property of the ADH-ALDH pathway was diminished in the presence of physiological concentration of EtOH among alcoholics, (34) likely owing to EtOH-ROL metabolic competition.
The majority of dietary retinoid is stored as retinyl ester (RE) mainly in hepatic stellate cells (HSCs). (35) These stored retinoids are distributed as ROL or RE to maintain serum retinoid concentration. The metabolism of uptaken ROL utilizes a two-step oxidative processe, in which medium-chain ADHs or retinol dehydrogenases catabolize ROL to retinaldehyde, followed by the second oxidation facilitated by ALDH to produce RA. (26) In particular to hepatocytes, ADH1 presumably plays a critical role in biogenesis of RA because of its relative abundance. (36, 37) RA governs various aspects of cell biology, especially in the regulation of cell differentiation and proliferation. (8) Thus, it is thought that RA has great influence on cells continuously undergoing proliferation and differentiation, such as professional immune cells. Indeed, RA is known to potentiate adaptive immunity by regulating T-cell proliferation, T helper 1-2 balancing, and cytotoxicity, as well as modulating B-cell proliferation and immunoglobulin production. (12) However, the role of RA in intracellular innate antiviral immunity, in which ISGs play a central role, has not been determined.
The contribution of RA in ISG induction appears not unique only to genes which nomenclature contains "RA inducible." (15, 17, 18) Indeed, a number of ISGs were noted to be up-regulated in the gene list obtained from transcriptome analysis of ATRA-treated leukemia cells. (38) Our results indicated that the effect of RA in ISG induction is gene specific rather than global upregulation (Fig. 6A) , suggesting that RA unlikely induces ISGs by secretion of IFNs nor confers activation of ISG induction pathways. In fact, we did not observe the phosphorylation of STATs and interferon regulatory factor 3 in ATRA-treated cells (data not shown) or ADH1B expression in Huh7 cells (Supporting Fig.  5D ,E). These notions collectively suggest that RA augments ISG expression at the gene promoter level. Our bioinformatics analysis demonstrated that the occurrence of RARE-DR5 in promoters of randomly selected genes was 2.11475 (-5,000 to 1500). Based on this number, we categorize ISGs into: (1) high DR5: >5 4 (82 ISGs, average 4.904 DR5 occurrence); (2) medium DR5: >52 and <4 (204 ISGs, average 2.441 DR5 occurrence); and (3) low DR5: <2 (160 ISGs, average 0.688 DR5 occurrence; Supporting Table 1 . These results indicate that RA can influence the expression of up to 88% of ISGs at the promoter level. Moreover, the occurrence of RARE-DR5 is significantly higher in nearly 20% of ISG promoters, further suggesting the role of RA in ISG expression. However, we have also noted that the RARE-DR5 frequency is not well correlated to the degree of ISG expression enhanced by the ADH-ALDH pathway ( Fig. 6A ; Supporting Table 1 ). This can be explained either by the cell-type-based differential response to RA or the discrepancy between the bioinformatics algorithms and the actual RAR-RXR occupancy. In fact, a study by others has noted differential RA-gene regulation in a celltype-specific manner and have shown that genomewide RAR binding loci do not correspond to expression of RA target genes. (39) The study attributed this discrepancy to the diversity of RAR-RXR binding sequence and/or chromatin topology.
Our study found that the ADH-ALDH pathway restricts HCV life cycle at either protein translation and/or genome replication stage. Because a similar pattern of HCV suppression was observed in IFN-treated HCV-SGR cells (data not shown), it is possible to speculate that the ISGs up-regulated by the ADH-ALDH pathway cooperatively drive this phenomenon. Because these two stages of viral life cycle have great influence on each other, further investigation is required in order to precisely define the mechanism of how RA-regulated ISGs exhibit antiviral activities.
Our results also imply the possibility that catabolism of RA by CYP2E1 may contribute to the impairments of ISGs expression. In addition, others have reported that the oxidative stress triggered by CYP2E1 impairs the IFN-mediated ISG expression through inhibition of STAT1 tyrosine phosphorylation, (40) indicating that CYP2E1 impairs ISG expression through multiple mechanisms. Furthermore, chronic liver diseases such as ALD and HCV infection are known to cause hypovitaminosis A as a result of the myofibroblastic transformation of HSCs. (29, 41) This mechanism likely further aggravates the impairment of RA-regulated ISG expression and thus explains the refractoriness to IFN-based antiviral therapy among advanced liver disease patients.
In summary, our study provided novel insights on the pathophysiology behind the synergistic liver disease progression between HCV infection and ALD. The insights obtained from our study are well applied to the high-risk demographics of HCV infection, given that nearly half of infected populations are heavy drinkers. Luciferase based reporter assays were carried out with a RARE sequence driven firefly luciferase reporter construct with Dual Luciferase Assay kit (Promega) (6) . The inducibility of RARE luciferase (Firefly) was normalized with the value from cotransfected CMV promoter driven Renilla luciferase to determine Relative Luciferase Unit (RLU).
Supplemental Information
Supplemental Figure 1. Identification of liver dominant ADH/ALDH isoforms. A-B.
Meta-analysis of ADH and ALDH expression: Nextbio was used to obtain the expression profiles of ADH and ALDH in public datasets. In Nextbio, high-quality public microarray dataset from GEO and other genomic data repositories were selected, normalized and pre-calculated for cross-study comparisons. Relative expression of a gene (fold-change) was calculated as the ratio between its expression in the selected tissue and its median expression across 52 tissue groups that are derived from 1067 arrays. For ADH/ALDH expression analysis, 11 liver (GSE3526, GSE1133, GSE2361, GSE7307), 4 kidney (GSE1133, GSE2361, GSE7307), 3 small intestine (GSE2361, GSE7307), 2 heart (GSE2361, GSE7307), 2 smooth muscle (GSE1133), 2 whole brain 
